Tumor Vaccines Market Size, Share, 2032
Tumor Vaccine Market Size and Forecast (2025 - 2032), By Product Type (Preventive Vaccines, Therapeutic Vaccines), By Technology (Dendritic Cell Vaccines, Protein/Peptide Vaccines, Viral Vector Vaccines, tumor Cell Vaccines, Others), By Cancer Type (Prostate Cancer, Cervical Cancer, Colorectal Cancer, Lung Cancer, Breast Cancer, Others), By End User (Hospitals, Specialty Clinics, Research Institutes), and Geography.
Market Overview:
The global tumor vaccine market is expected to reach a high CAGR of 11.2% over the Forecast Period 2025-2032, reaching a value of USD YY billion by 2032. North America dominates the market, accounting for YY% of the global share. Key metrics include increasing cancer incidence rates and rising investments in immuno-oncology research.
The tumor vaccine industry is expanding rapidly, owing to advances in cancer immunotherapy and personalised treatment. The increasing approval of innovative cancer vaccines, as well as a strong pipeline of candidates, are driving market growth. Growing knowledge about cancer prevention, as well as rising healthcare spending, are also driving market expansion.
Market Dynamics:
Market Trend: Personalised cancer vaccines gain traction. Tailored immunotherapies tailored to target specific tumor neoantigens are emerging as a promising cancer treatment strategy.
Personalised cancer vaccines are a game-changing innovation in oncology, combining cutting-edge genomic sequencing and bioinformatics to provide patient-specific immunotherapies. These vaccinations are intended to activate the immune system into recognising and attacking cancer cells based on their specific mutational profile. Recent clinical trials have yielded encouraging results, with better progression-free survival and overall survival rates in a variety of cancer types. Personalisation is being pushed by the knowledge that each patient's cancer is genetically unique, necessitating a bespoke strategy for optimal treatment outcomes. As sequencing technology grow more affordable and available, personalised cancer vaccinations are set to transform cancer care by providing a more targeted and perhaps more effective alternative to standard one-size-fits-all techniques.
Market Driver: Increasing cancer incidence and fatality rates worldwide. Rising cancer rates worldwide are driving need for novel prevention and treatment options, such as tumor vaccinations.
The global cancer burden continues to rise, with an expected 19.3 million new cases and 10 million cancer-related deaths reported in 2020. This concerning trend is mostly due to population increase, ageing demographics, and lifestyle choices like smoking, obesity, and physical inactivity. Cancer's increased incidence has produced an urgent need for more effective preventative and treatment alternatives, putting tumor vaccine at the forefront of comprehensive cancer care. Governments and healthcare organisations around the world are increasingly prioritising cancer control measures, committing significant money to research and development of new medicines. The rising cancer burden not only increases demand for tumor vaccine, but it also accelerates investment in clinical trials and regulatory clearances, driving innovation and market expansion in the oncology sector.
Market Restraint: Expensive development fees and lengthy regulatory approval processes Significant financial costs and time-consuming clinical studies present hurdles for industry participants seeking to bring new tumor vaccine to market.
tumor vaccine development is a difficult and resource-intensive procedure that necessitates significant financial commitments as well as extensive research. Bringing a new cancer vaccine from concept to market typically takes 10-15 years and costs more than $1 billion. The lengthy development cycle is primarily owing to tight regulatory regulations and the need for large-scale clinical trials to demonstrate safety and efficacy. The high failure rate in oncology treatment development increases the financial risks for pharmaceutical corporations. Furthermore, the intricacy of cancer biology and the necessity for personalised treatments in many circumstances complicate vaccine development. These factors can dissuade smaller biotech companies from entering the market and restrict the rate of innovation. Collaborations between academia, industry, and regulatory authorities are critical for addressing these difficulties, since they shorten the development process and lower costs while maintaining high safety requirements.
Segment Overview:
Therapeutic tumor vaccine have emerged as a viable cancer immunotherapy strategy, stimulating the immune system to recognise and target existing cancer cells. This area is rapidly expanding due to advances in tumor immunology and the development of innovative vaccination platforms.
Recent clinical trials have produced promising outcomes for therapeutic vaccinations in a variety of cancer forms, including melanoma, prostate cancer, and glioblastoma. For example, the FDA's approval of Sipuleucel-T (Provenge) for prostate cancer has cleared the way for additional research and development in this area. The therapeutic vaccines industry is likely to grow significantly, led by ongoing research into neoantigen-based vaccinations and combination treatments with checkpoint inhibitors.
Key figures show that the therapeutic vaccines segment will account for nearly YY% of the tumor vaccine market in 2023. We predict that this segment will grow at a compound annual growth rate (CAGR) of 13.5% between 2024 and 2031, outperforming the total market.
Regional Outlook:
North America leads the global tumor vaccines market share through superior healthcare infrastructure and strong R&D investments.
North America currently dominates the worldwide tumor vaccine market, owing to factors such as high healthcare spending, superior research facilities, and a strong presence of leading industry participants. The region's supremacy is due to favorable government measures encouraging cancer research, rapid adoption of breakthrough medications, and a high cancer incidence. The United States, in particular, leads in clinical trials for cancer vaccines, with multiple current research investigating novel techniques in immuno-oncology.
Recent advancements in the North American market include the FDA's fast approval process for promising cancer medicines, which has sped up the development of novel tumor vaccine. Furthermore, innovative partnerships between pharmaceutical businesses and research universities have strengthened the region's innovation pipeline.
North America accounted for almost 40% of global tumor vaccine market revenue in 2023. The area is expected to keep its lead throughout the forecast period, with a CAGR of 10.8% from 2024 to 2031.
Competitive Intelligence:
The tumor vaccine industry is characterised by fierce rivalry and rapid technological innovation. To preserve their market position, key players are prioritising strategic partnerships, mergers and acquisitions, and significant R&D investments. Leading businesses including as Merck & Co., GlaxoSmithKline, and Moderna have developed robust tumor vaccine pipelines, utilizing their immunology and oncology knowledge.
Market leaders are using a variety of techniques to broaden their product portfolios and global presence. For example, BioNTech's collaboration with Genentech on individualized neoantigen therapy has bolstered its position in personalized cancer vaccines. Similarly, Moderna's mRNA-based cancer vaccine programs have shown tremendous progress, with promising early-stage clinical findings.
According to Aurorawave Intellects Research, the top five competitors will account for almost YY% of the market in 2023. Merck & Co. leads with a market share of around YY%, followed by GlaxoSmithKline at YY%. Emerging players such as BioNTech and Moderna are fast gaining traction, thanks to their unique technology platforms and smart alliances.
The future view indicates a shift towards personalised cancer vaccines and combination medicines, with big manufacturers investing extensively in these areas to maintain their competitive advantage.
Analyst Opinion:
As a professional market research analyst, I predict that the tumor vaccine market will experience considerable expansion and transformation in the next years. Advanced genetics, artificial intelligence, and immunology are coming together to revolutionise cancer treatment approaches, with tumor vaccine leading the way.
The development of "off-the-shelf" neoantigen vaccines is a particularly interesting trend to follow. These vaccinations target common mutations seen in various cancer types, potentially providing a more cost-effective and accessible alternative to completely personalised immunisations. This strategy could significantly increase access to novel cancer medicines, particularly in areas with low healthcare resources.
Major Players:
-
Merck & Co., Inc.
-
GlaxoSmithKline plc
-
Moderna, Inc.
-
BioNTech SE
-
Genentech, Inc. (Roche Group)
-
CureVac N.V.
-
Advaxis, Inc.
-
Agenus Inc.
-
Genocea Biosciences, Inc.
-
Northwest Biotherapeutics, Inc.
-
OSE Immunotherapeutics
-
Vaccitech plc
Key Developments:
-
In May 2023, Moderna reported positive Phase 2 findings for their personalised cancer vaccine in combination with Merck's Keytruda for melanoma treatment.
-
In February 2024, BioNTech and Genentech launched a Phase 3 trial for their individualised neoantigen treatment in colorectal cancer patients
1. INTRODUCTION
1.1. Market Definitions & Study Assumptions
1.2. Market Research Scope & Segment
1.3. Research Methodology
2. EXECUTIVE SUMMARY
2.1. Market Overview & Insights
2.2. Segment Outlook
2.3. Region Outlook
3. COMPETITIVE INTELLIGENCE
3.1. Companies Financial Position
3.2. Company Benchmarking -- Key Players
3.3. Market Share Analysis -- Key Companies
3.4. Recent Companies Key Activities
3.5. Pricing Analysis
3.6. SWOT Analysis
4. Company Profiles (Key Companies list by Country) (Premium)
5. COMPANY PROFILES
5.1. Merck & Co., Inc.
5.2. GlaxoSmithKline plc
5.3. Moderna, Inc.
5.4. BioNTech SE
5.5. Genentech, Inc. (Roche Group)
5.6. CureVac N.V.
5.7. Advaxis, Inc.
5.8. Agenus Inc.
5.9. Genocea Biosciences, Inc.
5.10. Northwest Biotherapeutics, Inc.
5.11. OSE Immunotherapeutics
5.12. Vaccitech plc (*LIST NOT EXHAUSTIVE)
6. MARKET DYNAMICS
6.1. Market Trends
6.1.1. Personalized cancer vaccines gaining traction
6.1.2. Integration of artificial intelligence in vaccine development
6.1.3. Combination therapies with immune checkpoint inhibitors
6.2. Market Drivers
6.2.1. Increasing cancer incidence and mortality rates worldwide
6.2.2. Advancements in genomics and immunology
6.2.3. Growing investment in cancer research and development
6.3. Market Restraints
6.3.1. High development costs and lengthy regulatory approval processes
6.3.2. Challenges in identifying optimal neoantigens
6.4. Market Opportunities
6.5. Porter's Five Forces Analysis
6.5.1. Threat of New Entrants
6.5.2. Bargaining Power of Buyers/Consumers
6.5.3. Bargaining Power of Suppliers
6.5.4. Threat of Substitute Products
6.5.5. Intensity of Competitive Rivalry
6.6. Supply Chain Analysis
6.7. Value Chain Analysis
6.8. Trade Analysis
6.9. Pricing Analysis
6.10. Regulatory Analysis
6.11. Patent Analysis
6.12. SWOT Analysis
6.13. PESTLE Analysis
7. BY PRODUCT TYPE (MARKET SIZE/VALUE (US$ Mn), SHARE (%), MARKET FORECAST (%), YOY GROWTH (%)-- 2025-2032)
7.1. Preventive Vaccines
7.1.1. HPV Vaccines
7.1.2. Hepatitis B Vaccines
7.2. Therapeutic Vaccines
7.2.1. Autologous Cancer Vaccines
7.2.2. Allogeneic Cancer Vaccines
8. BY TECHNOLOGY (MARKET SIZE/VALUE (US$ Mn), SHARE (%), MARKET FORECAST (%), YOY GROWTH (%)-- 2025-2032)
8.1. Dendritic Cell Vaccines
8.2. Protein/Peptide Vaccines
8.3. Viral Vector Vaccines
8.4. tumor Cell Vaccines
8.5. Others
9. BY CANCER TYPE (MARKET SIZE/VALUE (US$ Mn), SHARE (%), MARKET FORECAST (%), YOY GROWTH (%)-- 2025-2032)
9.1. Prostate Cancer
9.2. Cervical Cancer
9.3. Colorectal Cancer
9.4. Lung Cancer
9.5. Breast Cancer
9.6. Others
10. BY END USER (MARKET SIZE/VALUE (US$ Mn), SHARE (%), MARKET FORECAST (%), YOY GROWTH (%)-- 2025-2032)
10.1. Hospitals
10.2. Specialty Clinics
10.3. Research Institutes
11. REGION (MARKET SIZE/VALUE (US$ Mn), SHARE (%), MARKET FORECAST (%), YOY GROWTH (%)-- 2025-2032)
11.1. North America
11.1.1. United States
11.1.2. Canada
11.1.3. Mexico
11.2. South America
11.2.1. Brazil
11.2.2. Argentina
11.2.3. Rest of South America
11.3. Europe
11.3.1. Germany
11.3.2. United Kingdom
11.3.3. France
11.3.4. Italy
11.3.5. Spain
11.3.6. Russia
11.3.7. Rest of Europe
11.4. Asia-Pacific
11.4.1. China
11.4.2. Japan
11.4.3. India
11.4.4. Australia
11.4.5. South Korea
11.4.6. Rest of Asia-Pacific
11.5. Middle-East
11.5.1. UAE
11.5.2. Saudi Arabia
11.5.3. Turkey
11.5.4. Rest of Middle East
11.6. Africa
11.6.1. South Africa
11.6.2. Egypt
11.6.3. Rest of Africa
*NOTE: All the regions mentioned in the scope will be provided with (MARKET SIZE/VALUE (US$ Mn), SHARE (%), MARKET FORECAST (%), YOY GROWTH (%)-- 2025-2032)
By Product Type:
- Preventive Vaccines
- Therapeutic Vaccines
By Technology:
- Dendritic Cell Vaccines
- Protein/Peptide Vaccines
- Viral Vector Vaccines
- tumor Cell Vaccines
- Others
By Cancer Type:
- Prostate Cancer
- Cervical Cancer
- Colorectal Cancer
- Lung Cancer
- Breast Cancer
- Others
By End User:
- Hospitals
- Specialty Clinics
- Research Institutes
By Region:
- North America
- Europe
- Asia-Pacific
- Latin America
- Middle East & Africa
Frequently Asked Questions
We at Aurorawave Intellects Market Report gives total market analysis that suit our customer business need and permit decision maker to run organizations without any problem. We have accomplished greatness in giving start to finish market research arrangements. Our detachment of industry specialists accumulate key data and get ready substance that lines up with our customer's business/specialty.
We at aurorawaveintellects.com offer mainly 3 types of licenses:
• Single User: Research Report copy can be distributed to a single user only
• Multi User: Research Report distribution is restricted up to 5 users.
• Corporate License :Research Report can be distributed across the company.
Based on the nature of the topic or research, the formats vary. The different formats of the report are as following:
• Word Document
• PPT
Following modes are available for making the payment:
• Online Payment (Visa Card, Master Card, Stripe)
• Razorpay
• Net Banking
• Bank Wire Transfer
Our customer service and research specialist team are available by phone and by email. Customer service hours are 24X7 Indian Standard Time (IST). You may reach us at:
• Email: info@aurorawaveintellects.com
• United Kingdom: ++91 7382742511